Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió A, Villamor N, Montserrat E.

Br J Haematol. 2016 Jan;172(1):48-55. doi: 10.1111/bjh.13788. Epub 2015 Nov 12.

PMID:
26559905
2.

Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.

Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J.

Blood Cancer J. 2015 Oct 2;5:e356. doi: 10.1038/bcj.2015.78. No abstract available.

3.

Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.

Calvo X, Nomdedeu M, Santacruz R, Martínez N, Costa D, Pereira A, Estrada N, Xicoy B, Esteve J, Nomdedeu B.

Leuk Res. 2015 Jul 23. pii: S0145-2126(15)30324-6. doi: 10.1016/j.leukres.2015.05.017. [Epub ahead of print]

PMID:
26354683
4.

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.

Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S.

Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. No abstract available.

5.

Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Royo C, Navarro A, Pinyol M, Rozman M, Pereira A, Villamor N, Aymerich M, López C, Carrió A, Montserrat E.

Haematologica. 2014 Oct;99(10):1599-604. doi: 10.3324/haematol.2014.107326. Epub 2014 Jun 27.

6.

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.

Santacruz R, Villamor N, Aymerich M, Martínez-Trillos A, López C, Navarro A, Rozman M, Beà S, Royo C, Cazorla M, Colomer D, Giné E, Pinyol M, Puente XS, López-Otín C, Campo E, López-Guillermo A, Delgado J.

Haematologica. 2014 May;99(5):873-80. doi: 10.3324/haematol.2013.099796. Epub 2014 Apr 3.

7.

New treatment options for chronic lymphocytic leukemia.

Delgado J, Baumann T, Santacruz R, Montserrat E.

Expert Opin Pharmacother. 2014 Apr;15(6):823-32. doi: 10.1517/14656566.2014.891017. Epub 2014 Feb 22. Review.

PMID:
24559127
8.

Skin lesions in a patient with blastic plasmacytoid dendritic cell neoplasm.

Dlouhy I, Santacruz R, Peña O.

Br J Haematol. 2014 Mar;164(6):758. doi: 10.1111/bjh.12712. Epub 2013 Dec 26. No abstract available.

PMID:
24372537
9.

Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration.

Delgado J, Ghita G, Baumann T, Santacruz R, Dlouhy I, Aymerich M, Rozman M, Creus N, Pereira A, Montserrat E.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):73-9. doi: 10.1016/j.clml.2013.08.003. Epub 2013 Oct 12.

PMID:
24126217
10.

Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion.

Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventín A, Luño E, Grau J, Hernandez JÁ, Marugán I, Ardanaz M, González T, Valiente A, Osma M, Calasanz MJ, Sanzo C, Carrió A, Ortega M, Santacruz R, Abrisqueta P, Abella E, Bosch F, Carbonell F, Solé F, Hernández JM, Espinet B; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC).

Br J Haematol. 2013 Oct;163(1):47-54. doi: 10.1111/bjh.12479. Epub 2013 Jul 19.

PMID:
23869550
11.

Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Biju KC, Santacruz RA, Chen C, Zhou Q, Yao J, Rohrabaugh SL, Clark RA, Roberts JL, Phillips KA, Imam SZ, Li S.

Neurosci Lett. 2013 Feb 22;535:24-9. doi: 10.1016/j.neulet.2012.12.034. Epub 2013 Jan 4.

12.

Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib.

Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B, Gorin NC.

Haematologica. 2007 Jan;92(1):e9-10.

13.

Hemispheric asymmetry in lexical decisions: the effects of grammatical class and imageability.

Nieto A, Santacruz R, Hernández S, Camacho-Rosales J, Barroso J.

Brain Lang. 1999 Dec;70(3):421-36.

PMID:
10600228
14.

Blood types in cattle of Iberian ancestry and in Holsteins at various altitudes.

Ramirez G, Miller WJ, Bittle PA, Hidalgo A, Santacruz R, Colice G.

Am J Vet Res. 1992 Jul;53(7):1248-52.

PMID:
1497198
15.

Blood biochemical characteristics of cattle at sea level and at moderately high altitude (3,000 m).

Ramirez G, Bittle PA, Colice GL, Santacruz R, Hidalgo A, Noguera I, Agosti SJ, Foulis PR.

Am J Vet Res. 1992 Apr;53(4):547-50.

PMID:
1586027
16.

[On a case of Wilson's disease].

Sicilia JJ, Aguirre M, Santacruz R, Torres JA.

Rev Clin Esp. 1968 Aug 15;110(3):263-6. Spanish. No abstract available.

PMID:
5747556

Supplemental Content

Loading ...
Support Center